Key takeaways about AOD-9604 for weight loss
- AOD-9604 is a lab-made fragment of human growth hormone (176–191) researched for effects on fat metabolism, not a full growth hormone.
- Human trials are limited and mixed; early studies did not show consistent, clinically meaningful weight loss outcomes.
- It is not TGA-approved for obesity or weight management in Australia; access and advertising are restricted.
- Safety data over the long term are limited. Mild reactions like injection site irritation and headache are reported; unknowns remain.
- Approved weight loss injections (GLP-1 and dual agonists) have stronger evidence and defined indications. See comparisons below.
What is AOD-9604?
AOD-9604 is a synthetic peptide derived from the C‑terminal fragment (amino acids 176–191) of human growth hormone. It was developed to explore whether it could promote lipolysis (fat breakdown) and inhibit lipogenesis (fat creation) without the broader growth hormone effects on blood sugar, fluid retention or growth pathways.
Most of the early rationale comes from mechanistic and preclinical work. The clinical question many searchers have is whether this translates into meaningful, sustained weight loss in humans. The short answer: current human evidence is limited and inconsistent.
Does AOD-9604 work for weight loss? What the research shows
Studies in humans to date have been small and have not consistently demonstrated clinically significant weight loss or reductions in fat mass compared with placebo. Earlier industry-led trials reported failure to meet primary endpoints for fat loss, and later investigations have not resolved the uncertainty.
Typical themes across the literature:
- Limited sample sizes and short durations make it difficult to draw strong conclusions.
- Endpoints such as total body weight, fat mass, or waist circumference have shown inconsistent or minimal differences versus placebo.
- No regulatory body in Australia has approved AOD-9604 for obesity or weight management based on current evidence.
Bottom line for searchers: evidence for AOD-9604 as a stand‑alone weight loss therapy in humans remains weak compared to approved options.
Safety, side effects and unknowns
Reported side effects with AOD-9604 include injection site reactions (redness, tenderness), headache, nausea and fatigue in some users. Because long‑term, large-scale human safety data are lacking, important unknowns remain, including potential metabolic effects with extended use and interactions with other medicines or conditions.
General cautions typically raised by clinicians:
- Not advised in pregnancy or breastfeeding due to insufficient safety data.
- Caution with endocrine or metabolic disorders until supervised medical advice is obtained.
- Avoid sourcing from unverified sellers due to contamination, mislabeling and dosing risks.
Educational note: This page is general information only and not medical advice. Speak with a qualified health professional about your situation.
Is AOD-9604 legal in Australia? Access and rules
AOD-9604 is not approved by the TGA for weight loss. Access, importation and advertising are restricted, and unsupervised online sales often breach Australian rules. If you see “research-only” or grey‑market offers, understand the seizure and safety risks before acting. For specifics, read:
AOD-9604 vs approved medical weight loss options
Approved prescription options such as GLP‑1 and dual‑agonist medicines have substantially stronger human evidence for weight loss, including average outcomes in the 10–20%+ range under medical supervision. If your goal is clinically meaningful weight reduction, compare AOD-9604 with established therapies:
Common online claims and how to read them
- “Targets belly/stubborn fat” — Human data do not robustly support site‑specific fat loss. Be cautious with spot‑reduction claims.
- “Boosts metabolism without side effects” — Mechanistic theories exist, but long‑term human safety data are limited.
- “Similar results to GLP‑1s” — Not supported by comparative human evidence or regulatory approvals.
For focused deep dives on popular claims, see:
Who should avoid or seek medical advice first
- Pregnant or breastfeeding individuals.
- People with active endocrine disorders, uncontrolled diabetes or complex metabolic disease.
- Anyone taking multiple prescription medicines or with a history of medication sensitivity.
- Athletes subject to anti‑doping rules should check prohibited lists and seek formal guidance.
More AOD-9604 resources
Frequently asked questions
What is AOD-9604?
AOD-9604 is a synthetic fragment (176–191) of human growth hormone researched for potential effects on fat metabolism. It is not approved for weight loss in Australia.
Does AOD-9604 lead to meaningful weight loss?
Human trials are limited and mixed. Early studies failed to meet primary fat‑loss endpoints, and results since then have not established consistent, clinically meaningful weight reduction.
What side effects are reported?
Injection site reactions, headache, nausea and fatigue have been reported. Long‑term safety in humans remains uncertain.
Is AOD-9604 legal to buy in Australia?
It is not TGA‑approved and access is restricted. Learn more in our legal overview and safer access guide linked above.
How does AOD-9604 compare to GLP‑1s like semaglutide?
GLP‑1 and dual‑agonist medicines have strong human evidence and approval for weight management. AOD‑9604 does not. See our comparison pages for details.
Can it target belly or stubborn fat?
Spot‑reduction claims are not supported by robust human data. Be cautious with marketing that promises area‑specific fat loss.
Where can I ask a personalised question?
Use the form below and our team will help you find the most relevant next page or provider pathway.
Get guidance on weight loss treatments in Australia
Send your question and we’ll point you to evidence‑based resources and safer access pathways. No spam. Educational help only.
Your details are used to answer your enquiry only.
Final takeaway
If you’re researching aod 9604 for weight loss, be aware that human evidence is limited and inconsistent, long‑term safety is unclear, and it is not approved for obesity management in Australia. Consider comparing it with established GLP‑1 or dual‑agonist therapies that have robust clinical outcomes and defined safety guidance.